Evidence map›Paper›PMID 33683002›Full record

ArticleAmerican journal of medical genetics. Part A2021

Congenital polyvalvular disease expands the cardiac phenotype of the RASopathies.

Dena R Matalon, David A Stevenson, Elizabeth J Bhoj, Avni B Santani, Beth Keena, Meryl S Cohen, Angela E Lin, Sarah E Sheppard, Elaine H Zackai

Open access · greenAbstract read
In one paragraph

Article in American journal of medical genetics. Part A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Cardiovascular aspects of Noonan syndrome and related disorders.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dena R MatalonDivision of Medical Genetics, Stanford University, Stanford, California, USA.ORCID 0000-0001-8616-7239
David A StevensonDivision of Medical Genetics, Stanford University, Stanford, California, USA.
Elizabeth J BhojDivision of Human Genetics and Molecular Biology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-5748-3507
Avni B SantaniDivision of Human Genetics and Molecular Biology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Beth KeenaDivision of Human Genetics and Molecular Biology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Meryl S CohenDivision of Cardiology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Angela E LinMedical Genetics, MassGeneral Hospital for Children, Boston, Massachusetts, USA.ORCID 0000-0002-1145-4572
Sarah E SheppardDivision of Human Genetics and Molecular Biology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Elaine H ZackaiDivision of Human Genetics and Molecular Biology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Children's Hospital of Philadelphia · USStanford University · USMassachusetts General Hospital · US

Funding

NRSA Training CoreTL1TR001880 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI MEAGHER, EMMA ANNE · 2016 to 2025
$10.0M
NCATS NIH HHS TL1 TR001880
6 · The paper itself

Abstract

The RASopathies are a group of similar genetic syndromes with cardiovascular abnormalities, characteristic facial features, short stature, abnormalities of the skin and musculoskeletal system, and variable neurodevelopmental challenges. The most common cardiovascular abnormalities include pulmonary valvular stenosis and hypertrophic cardiomyopathy. Congenital polyvalvular disease (CPVD) refers to congenital dysplasia of two or more cardiac valves. We diagnosed a RASopathy in two individuals with CPVD and noted that CPVD in RASopathies has rarely been reported in the literature. Thus, we performed a retrospective chart review and literature review to investigate the association and characterize the phenotype of CPVD in the RASopathies. CPVD was present in 2.5% (n = 6/243) of individuals in our RASopathy cohort. Involvement of two cardiac valves, commonly the aortic and pulmonic valves, was seen in the majority of individuals (6/8; 75%) in our cohort, but only 27% (3/11) of reported CPVD and RASopathy cases in the literature. CPVD should be considered an associated cardiovascular phenotype of the RASopathies, which has implications for diagnosis and management.

Indexed as

AdolescentAortic ValveCardiomyopathy, HypertrophicCardiovascular AbnormalitiesChildChild, PreschoolDwarfismFaciesFemaleHeart Defects, CongenitalHumansInfantInfant, NewbornMaleMusculoskeletal AbnormalitiesNoonan SyndromeBRAF protein, humanProtein Tyrosine Phosphatase, Non-Receptor Type 11Proto-Oncogene Proteins B-rafPTPN11 protein, humanras Proteinscardiofaciocutaneous (CFC) syndromeconnective tissue diseaseNoonan syndromepolyvalvular diseasePTPN11RASopathies

Identifiers

PMID33683002
PMCPMC8711298
OpenAlexW3134614922

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.